Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INF 108

Next Previous
Drug Profile

INF 108

Alternative Names: INF-108

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Infinant Health
  • Class Bacteria
  • Mechanism of Action Bacteria replacements; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Necrotising enterocolitis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Necrotising enterocolitis

Most Recent Events

  • 19 May 2025 Infinant Health has patent protection for "The method that the incidence of disease of the necrotizing enterocolitis of baby, child or children is reduced using human milk oligosaccharides." in the Malaysia, USA, Mexico,Philippines, Canada, China and Singapore (prior to May 2025)
  • 07 May 2025 Infinant Health has patent pending for "The method that the incidence of disease of the necrotizing enterocolitis of baby, child or children is reduced using human milk oligosaccharides." in the multiple countries worldwide (prior to May 2025)
  • 07 May 2025 Preclinical study in Necrotising enterocolitis (In infants, Prevention) in USA (unspecified route) prior to May 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top